Pharma, R&D

Teva’s migraine drug can’t stop another bad R&D headache as researchers scrap a failed PhIII program for Ajovy

Teva’s marketing horizon for its recently approved migraine drug just got smaller.

The generics company $TEVA with a pipeline, Ajovy’s OK last fall was one of the rare R&D bright spots at the company, which has been undergoing a wrenching restructuring in the last 18 months. But researchers for the company said on Tuesday that they are scrapping a Phase III trial for episodic cluster headaches after the drug (fremanezumab) failed to clear a futility test.

Teva had already given up on a chronic cluster headache study last summer, but remains in the clinic for post-traumatic headache.

The setback will cost Teva some of the badly needed upside on this drug, which the Bloomberg consensus set at about $500 million for 2022 sales — Leerink projected $629 million in 2023 — as the drugs in the class divvy up a multibillion-dollar market. This drug was the second CGRP therapy to get past regulators, following Aimovig from Novartis $NVS and Amgen $AMGN, now the subject of a legal battle over the future of their alliance.

Teva’s loss here could be its rivals’ gain. Eli Lilly recently snagged a priority review for its CGRP contender Emgality as a treatment for cluster headaches, offering some mixed data from that program. 

Alder $ALDR, the last of the CGRP contenders, announced just hours ago that their pitch has been accepted by the FDA. And the little company could disrupt a migraine market where the price is lined up at $6,900 a year.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->